ArticleBMJ open2025

Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for primary advanced or recurrent endometrial cancer: a prospective single-arm open-label phase II clinical trial.

Jie Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.